# Bioequivalence Study to Compare Empagliflozin/ Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg

> **NCT07694115** · PHASE1 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 40 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** Empagliflozin / Metformin Extended-Release Tablet
- **DRUG:** Synjardy XR tablets

## Key facts

- **NCT ID:** NCT07694115
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2026-05-07
- **Primary completion:** 2026-06-29
- **Final completion:** 2026-07-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07694115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07694115, "Bioequivalence Study to Compare Empagliflozin/ Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07694115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*